Budget impact analysis of chronic kidney disease mass screening test in Japan

Masahide Kondo, Kunihiro Yamagata, Shu Ling Hoshi, Chie Saito, Koichi Asahi, Toshiki Moriyama, Kazuhiko Tsuruya, Tsuneo Konta, Shouichi Fujimoto, Ichiei Narita, Kenjiro Kimura, Kunitoshi Iseki, Tsuyoshi Watanabe

研究成果: ジャーナルへの寄稿記事

7 引用 (Scopus)

抄録

Results: Annual budget impacts of mass screening compared with do-nothing scenario were calculated as ¥79–¥−1,067 million for dipstick test only, ¥2,505–¥9,235 million for serum Cr assay only and ¥2,517–¥9,251 million for the use of both during a 15-year period. Annual budget impacts associated with the reforms were calculated as ¥975–¥4,129 million for mandating serum Cr assay in addition to the currently used mandatory dipstick test, and ¥963–¥4,113 million for mandating serum Cr assay only and abandoning dipstick test.

Conclusions: Estimated values associated with the reform from ¥963–¥4,129 million per year over 15 years are considerable amounts of money under limited resources. The most impressive finding of this study is the decreasing additional expenditures in dipstick test only scenario. This suggests that current policy which mandates dipstick test only would contain medical care expenditure.

Background: Our recently published cost-effectiveness study on chronic kidney disease mass screening test in Japan evaluated the use of dipstick test, serum creatinine (Cr) assay or both in specific health checkup (SHC). Mandating the use of serum Cr assay additionally, or the continuation of current policy mandating dipstick test only was found cost-effective. This study aims to examine the affordability of previously suggested reforms.

Methods: Budget impact analysis was conducted assuming the economic model would be good for 15 years and applying a population projection. Costs expended by social insurers without discounting were counted as budgets.

元の言語英語
ページ(範囲)885-891
ページ数7
ジャーナルClinical and Experimental Nephrology
18
発行部数6
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Mass Screening
Budgets
Chronic Renal Insufficiency
Creatinine
Japan
Serum
Health Expenditures
Economic Models
Costs and Cost Analysis
Insurance Carriers
Cost-Benefit Analysis
Health

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

これを引用

Kondo, M., Yamagata, K., Hoshi, S. L., Saito, C., Asahi, K., Moriyama, T., ... Watanabe, T. (2014). Budget impact analysis of chronic kidney disease mass screening test in Japan. Clinical and Experimental Nephrology, 18(6), 885-891. https://doi.org/10.1007/s10157-014-0943-8

Budget impact analysis of chronic kidney disease mass screening test in Japan. / Kondo, Masahide; Yamagata, Kunihiro; Hoshi, Shu Ling; Saito, Chie; Asahi, Koichi; Moriyama, Toshiki; Tsuruya, Kazuhiko; Konta, Tsuneo; Fujimoto, Shouichi; Narita, Ichiei; Kimura, Kenjiro; Iseki, Kunitoshi; Watanabe, Tsuyoshi.

:: Clinical and Experimental Nephrology, 巻 18, 番号 6, 01.01.2014, p. 885-891.

研究成果: ジャーナルへの寄稿記事

Kondo, M, Yamagata, K, Hoshi, SL, Saito, C, Asahi, K, Moriyama, T, Tsuruya, K, Konta, T, Fujimoto, S, Narita, I, Kimura, K, Iseki, K & Watanabe, T 2014, 'Budget impact analysis of chronic kidney disease mass screening test in Japan', Clinical and Experimental Nephrology, 巻. 18, 番号 6, pp. 885-891. https://doi.org/10.1007/s10157-014-0943-8
Kondo, Masahide ; Yamagata, Kunihiro ; Hoshi, Shu Ling ; Saito, Chie ; Asahi, Koichi ; Moriyama, Toshiki ; Tsuruya, Kazuhiko ; Konta, Tsuneo ; Fujimoto, Shouichi ; Narita, Ichiei ; Kimura, Kenjiro ; Iseki, Kunitoshi ; Watanabe, Tsuyoshi. / Budget impact analysis of chronic kidney disease mass screening test in Japan. :: Clinical and Experimental Nephrology. 2014 ; 巻 18, 番号 6. pp. 885-891.
@article{586087cbf60c4195b5be27bbed4cd260,
title = "Budget impact analysis of chronic kidney disease mass screening test in Japan",
abstract = "Results: Annual budget impacts of mass screening compared with do-nothing scenario were calculated as ¥79–¥−1,067 million for dipstick test only, ¥2,505–¥9,235 million for serum Cr assay only and ¥2,517–¥9,251 million for the use of both during a 15-year period. Annual budget impacts associated with the reforms were calculated as ¥975–¥4,129 million for mandating serum Cr assay in addition to the currently used mandatory dipstick test, and ¥963–¥4,113 million for mandating serum Cr assay only and abandoning dipstick test.Conclusions: Estimated values associated with the reform from ¥963–¥4,129 million per year over 15 years are considerable amounts of money under limited resources. The most impressive finding of this study is the decreasing additional expenditures in dipstick test only scenario. This suggests that current policy which mandates dipstick test only would contain medical care expenditure.Background: Our recently published cost-effectiveness study on chronic kidney disease mass screening test in Japan evaluated the use of dipstick test, serum creatinine (Cr) assay or both in specific health checkup (SHC). Mandating the use of serum Cr assay additionally, or the continuation of current policy mandating dipstick test only was found cost-effective. This study aims to examine the affordability of previously suggested reforms.Methods: Budget impact analysis was conducted assuming the economic model would be good for 15 years and applying a population projection. Costs expended by social insurers without discounting were counted as budgets.",
author = "Masahide Kondo and Kunihiro Yamagata and Hoshi, {Shu Ling} and Chie Saito and Koichi Asahi and Toshiki Moriyama and Kazuhiko Tsuruya and Tsuneo Konta and Shouichi Fujimoto and Ichiei Narita and Kenjiro Kimura and Kunitoshi Iseki and Tsuyoshi Watanabe",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10157-014-0943-8",
language = "English",
volume = "18",
pages = "885--891",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Budget impact analysis of chronic kidney disease mass screening test in Japan

AU - Kondo, Masahide

AU - Yamagata, Kunihiro

AU - Hoshi, Shu Ling

AU - Saito, Chie

AU - Asahi, Koichi

AU - Moriyama, Toshiki

AU - Tsuruya, Kazuhiko

AU - Konta, Tsuneo

AU - Fujimoto, Shouichi

AU - Narita, Ichiei

AU - Kimura, Kenjiro

AU - Iseki, Kunitoshi

AU - Watanabe, Tsuyoshi

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Results: Annual budget impacts of mass screening compared with do-nothing scenario were calculated as ¥79–¥−1,067 million for dipstick test only, ¥2,505–¥9,235 million for serum Cr assay only and ¥2,517–¥9,251 million for the use of both during a 15-year period. Annual budget impacts associated with the reforms were calculated as ¥975–¥4,129 million for mandating serum Cr assay in addition to the currently used mandatory dipstick test, and ¥963–¥4,113 million for mandating serum Cr assay only and abandoning dipstick test.Conclusions: Estimated values associated with the reform from ¥963–¥4,129 million per year over 15 years are considerable amounts of money under limited resources. The most impressive finding of this study is the decreasing additional expenditures in dipstick test only scenario. This suggests that current policy which mandates dipstick test only would contain medical care expenditure.Background: Our recently published cost-effectiveness study on chronic kidney disease mass screening test in Japan evaluated the use of dipstick test, serum creatinine (Cr) assay or both in specific health checkup (SHC). Mandating the use of serum Cr assay additionally, or the continuation of current policy mandating dipstick test only was found cost-effective. This study aims to examine the affordability of previously suggested reforms.Methods: Budget impact analysis was conducted assuming the economic model would be good for 15 years and applying a population projection. Costs expended by social insurers without discounting were counted as budgets.

AB - Results: Annual budget impacts of mass screening compared with do-nothing scenario were calculated as ¥79–¥−1,067 million for dipstick test only, ¥2,505–¥9,235 million for serum Cr assay only and ¥2,517–¥9,251 million for the use of both during a 15-year period. Annual budget impacts associated with the reforms were calculated as ¥975–¥4,129 million for mandating serum Cr assay in addition to the currently used mandatory dipstick test, and ¥963–¥4,113 million for mandating serum Cr assay only and abandoning dipstick test.Conclusions: Estimated values associated with the reform from ¥963–¥4,129 million per year over 15 years are considerable amounts of money under limited resources. The most impressive finding of this study is the decreasing additional expenditures in dipstick test only scenario. This suggests that current policy which mandates dipstick test only would contain medical care expenditure.Background: Our recently published cost-effectiveness study on chronic kidney disease mass screening test in Japan evaluated the use of dipstick test, serum creatinine (Cr) assay or both in specific health checkup (SHC). Mandating the use of serum Cr assay additionally, or the continuation of current policy mandating dipstick test only was found cost-effective. This study aims to examine the affordability of previously suggested reforms.Methods: Budget impact analysis was conducted assuming the economic model would be good for 15 years and applying a population projection. Costs expended by social insurers without discounting were counted as budgets.

UR - http://www.scopus.com/inward/record.url?scp=84919838538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919838538&partnerID=8YFLogxK

U2 - 10.1007/s10157-014-0943-8

DO - 10.1007/s10157-014-0943-8

M3 - Article

C2 - 24515308

AN - SCOPUS:84919838538

VL - 18

SP - 885

EP - 891

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 6

ER -